Obesity-focused Aardvark Therapeutics is hoping to raise $100 million in an initial public offering (IPO), according to a US Securities and Exchange Commission (SEC) filing. The Californian biopharma ...

10 x 15 in. (25.4 x 38.1 cm.) Subscribe now to view details for this work, and gain access to over 18 million auction results. Purchase One-Day Pass ...

Obesity drug developer Aardvark Therapeutics (NASDAQ:AARD) has filed for a $100M initial public offering. Aardvark (NASDAQ:AARD) didn't disclose any terms in its SEC filing, but indicated in its ...

The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics revealing plans to go public while Hong Kong-listed Ascentage Pharma joins ...

In a 2025 punctuated by news from the weight-loss space, obesity-focused biotech Aardvark Therapeutics filed for an IPO Thursday, following competitor Metsera, which announced its own bid earlier this ...